Alzheon names board member
This article was originally published in Scrip
Executive Summary
Alzheon, a clinical-stage biopharmaceutical company focused on brain health, memory and aging, has appointed Dr David Nikodem, to its board of directors. Dr Nikodem is a senior representative of the global healthcare-focused investment firm Ally Bridge Group.